Meningococcal burden of disease in Argentina: 10 years epidemiologic review

Hum Vaccin Immunother. 2023 Aug 1;19(2):2237391. doi: 10.1080/21645515.2023.2237391.

Abstract

Invasive meningococcal disease (IMD) is an uncommon but serious and potentially fatal condition, mainly affecting infants. In 2017, Argentina introduced a vaccination program against serogroups A, C, W and Y (MenACWY) for infants aged 3, 5 and 15 months and adolescents aged 11 years. The objective of this study was to review the burden of IMD in Argentina in 2010-2019. Data were obtained from national surveillance databases, and the study estimated IMD incidence, mortality, case-fatality rates, and serogroup distributions across age groups. A total of 1,972 IMD cases were reported in the study period, with the highest incidence in infants aged < 1 year. Incidence peaked in 2013 and subsequently declined. Mortality rates were 18 times higher in infants than in other age groups, reflecting the high impact of IMD in this age group. The case-fatality rate was 8.5% on average and increased with age. The proportion of notified cases with serogroup identification increased over the period, reaching 91% in 2019. The most common serogroups over the study period were serogroup B (48%) and serogroup W (42%), with an increase in B relative to W since 2015. In infants aged < 1 year, the proportion of serogroup B increased in recent years, reaching around 70% of characterized cases in 2018-2019. These results show the dynamism of IMD and indicate the importance of vaccination at an early age and offering protection against predominant serogroups. These data are valuable to support evidence-based decision-making in healthcare.

Keywords: Argentina; Children; disease burden; meningococcal disease; serogroups.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Argentina / epidemiology
  • Cost of Illness
  • Databases, Factual
  • Health Facilities
  • Humans
  • Infant
  • Meningococcal Infections* / epidemiology
  • Meningococcal Infections* / prevention & control

Grants and funding

GlaxoSmithKline Biologicals SA funded this study [VEO-000225]. GlaxoSmithKline Biologicals SA took in charge all costs associated with the development and publication of this manuscript.